Compare SID & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SID | FDMT |
|---|---|---|
| Founded | 1941 | 2013 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 833.8M | 695.3M |
| IPO Year | 2002 | 2019 |
| Metric | SID | FDMT |
|---|---|---|
| Price | $0.51 | $10.14 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | $1.17 | ★ $28.09 |
| AVG Volume (30 Days) | ★ 10.8M | 855.5K |
| Earning Date | 11-12-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $85,209,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.87 | $20.79 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 230194.60 |
| 52 Week Low | $0.55 | $6.96 |
| 52 Week High | $2.20 | $16.93 |
| Indicator | SID | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 24.87 | 37.51 |
| Support Level | N/A | $8.43 |
| Resistance Level | $1.34 | $10.61 |
| Average True Range (ATR) | 0.07 | 0.85 |
| MACD | -0.02 | -0.15 |
| Stochastic Oscillator | 1.23 | 1.07 |
Companhia Siderurgica Nacional is an integrated steel producer. together with its subsidiaries operates in five main business segments: Steel industry: production and marketing of flat and long steels; Mining: extraction, processing and marketing of iron ore, tin, limestone and dolomite; Cement: production and commercialization of bagged and bulk cement, in addition to aggregates, concrete, and other related products; Energy: generation and sale of energy from almost all renewable sources; and Logistics: participations port concessions and fleets of road transport vehicles. The group generates the majority of its revenue from the Steel industry segment. Geographically, it derives a majority of revenue from Asia.
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).